Barclays
TBIO

Barclays’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Barclays’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-48,208
Closed -$1.33M – 5114
2021
Q2 		$1.33M Sell
48,208
-49,587
-51% -$974K ﹤0.01% 2474
2021
Q1 		$1.61M Sell
97,795
-135,405
-58% -$3.08M ﹤0.01% 2468
2020
Q4 		$4.3M Buy
233,200
+160,161
+219% +$2.87M ﹤0.01% 1615
2020
Q3 		$994K Buy
73,039
+25,791
+55% +$398K ﹤0.01% 2703
2020
Q2 		$847K Buy
47,248
+35,746
+311% +$539K ﹤0.01% 2910
2020
Q1 		$115K Sell
11,502
-28,327
-71% -$232K ﹤0.01% 4711
2019
Q4 		$324K Buy
39,829
+21,316
+115% +$197K ﹤0.01% 4650
2019
Q3 		$183K Sell
18,513
-425
-2% -$4.01K ﹤0.01% 5037
2019
Q2 		$239K Buy
18,938
+10,090
+114% +$106K ﹤0.01% 4955
2019
Q1 		$90K Buy
8,848
+2,138
+32% +$16.4K ﹤0.01% 5448
2018
Q4 		$50K Buy
6,710
+3,039
+83% +$22.3K ﹤0.01% 5480
2018
Q3 		$37K Buy
+3,671
New +$42.7K ﹤0.01% 6238

Barclays's TBIO Position: Q3 2021 in Review

Barclays sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 48,208 shares — an estimated $1.33M sold.

Barclays first reported a position in TBIO in Q3 2018 and held it in 12 quarters. The position peaked at $4.3M in Q4 2020. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

  • Barclays reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Barclays sold 48,208 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $1.33M.
  • Barclays first reported a position in Translate Bio, Inc. Common Stock in Q3 2018 and held it in 12 quarters.
  • Barclays's Translate Bio, Inc. Common Stock position peaked at $4.3M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on Barclays's 13F filing for Q3 2021, filed 9 Nov 2021.